尽管过去10年间药物研发模式有了巨大革新,但最终成功上市的新药品种仍很少,而研发成本较以往又更高了。本国药品售价同时承受国内政治与国外低成本竞争的双重压力。而且,药企自身目前还存在着诸多局限:如缺少与病患的相互沟通;药物发现与开发部门间存在的理念分歧;企业细化;企 Despite the tremendous innovation in the drug discovery model over the past decade, the number of new drug products that will eventually be successfully marketed is still small, and R & D costs are even higher than ever before. The domestic drug prices at the same time withstand the dual pressures of domestic politics and foreign low-cost competition. Moreover, the pharmaceutical companies themselves still exist many limitations: such as the lack of mutual communication with patients; drug discovery and development departments exist differences between the concept; enterprise refinement; enterprises